Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue: +13.3%
EPS: −51.5%
Free cash flow: +364.6%
Total debt: −4.00%

Quarter to September 2026, against a year earlier

Dividend growth 5 yrs

67.70 0.13 +0.19%

Follow RPRX

Alert me

Market cap: $39.0B
P/E: 44.8×
Fwd P/E: 27.3×
Dividend yield: 1.37%
F-score: 5/9
Altman Z: 1.61
Beneish M: −2.83
Dividend safety: 41/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Royalty Pharma PLC (RPRX) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Royalty Pharma PLC (RPRX) trades at a price to free cash flow of 23.3×. Over the past ten years it has ranged from 0.0× (March 2022) to 177× (December 2020); the current reading is higher than 80% of that period. That is below the Biotechnology industry median of 24.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RPRX/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Royalty Pharma PLC price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RPRX/metrics/price-to-free-cash-flow">Royalty Pharma PLC (RPRX) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	4.7×	13.62%
FY2024	4.2×	9.85%
FY2023	3.8×	(53.46%)
FY2022	8.1×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—

Period	Price to free cash flow	Change
Sep 2026	20.1×	5.64%
Jun 2026	19.0×	8.69%
Mar 2026	17.5×	271.14%
Dec 2025	4.7×	6.37%
25 more quarters	Free account

Against its own ten years

Low 0.0× High 177×

Ten-year median 6.2×

Current reading's percentile 80

Company	Price to free cash flow
ROIV Roivant Sciences Ltd. compare	n/m
GMAB Genmab A/S Sponsored ADR compare	n/m
BNTX BioNTech SE Sponsored ADR compare	n/m
RVMD Revolution Medicines, Inc. compare	n/m
INSM Insmed, Inc. compare	n/m
RPRX Royalty Pharma PLC	23.3×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	30.4×
INCY Incyte Corporation compare	35.3×
ARGX argenex SE compare	41.0×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Royalty Pharma PLC (RPRX) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on RPRX

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on RPRX

Stockrow Weekly